BigHat Biosciences, a San Mateo, CA-bases biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, announced that it raised a $75 million Series B funding.
The round was led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, and GRIDS Capital, among others.
The fund will be used to scale the capacity of MillinerTM, an integrated AI/ML- wet lab platform, advance therapeutic programs toward human clinical trials, aggressively hire drug discovery and development talent, and accelerate strategic collaborations with flagship partners
Company: BigHat Biosciences, Inc
Raised: $75.0 M
Round: Series B
Funding Month: July 2022
Lead Investors: Section 32
Additional Investors: Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital
Company Website: https://www.bighatbio.com/
Software Category: AI-enabled antibody design platform
About the Company: Founded in 2019, BigHat Biosciences is a Series B biotechnology company in the San Francisco Bay Area. BigHat is led by a team of experts spanning machine learning, molecular biology, drug development, and medicine. BigHat is supported by a cadre of world leaders, including a Nobel Laureate and the physician-scientist that brought Herceptin to market. To date, BigHat has raised $105 million from top investors led by Section 32, Andreessen Horowitz, and 8VC and is quickly succeeding in partnerships with large biopharma partners. In addition to these collaborations, BigHat has active therapeutic programs spanning multiple domains of human health, including inflammation, oncology, and infectious diseases in preclinical studies.